News
Cash-back rewards platform Ibotta (NYSE:IBTA) fell short of the market’s revenue expectations in Q2 CY2025, with sales ...
2d
Fintel on MSNB of A Securities Downgrades Ibotta (IBTA)
Fintel reports that on August 14, 2025, B of A Securities downgraded their outlook for Ibotta (NYSE:IBTA) from Neutral to ...
2d
Fintel on MSNGoldman Sachs Downgrades Ibotta (IBTA)
Fintel reports that on August 14, 2025, Goldman Sachs downgraded their outlook for Ibotta (NYSE:IBTA) from Buy to Neutral.
Ibotta Inc (IBTA) focuses on strategic transformation and client engagement despite short-term revenue challenges.
Ibotta reports declining revenue & margins, ending growth streak. User growth remains strong, but monetization drops, ...
StockStory.org on MSN4d
Ibotta (IBTA) Q2 Earnings: What To Expect
Cash-back rewards platform Ibotta (NYSE:IBTA) will be reporting earnings this Wednesday after the bell. Here’s what to look ...
Cash-back rewards platform Ibotta (NYSE:IBTA) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 2.2% year on year to $86.03 million. Next quarter’s revenue guidance of ...
Shares of Ibotta ( NYSE: IBTA) were spiraling lower as the company reported disappointing results for the second quarter and ...
Ibotta (IBTA) delivered earnings and revenue surprises of -55.56% and -4.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ARK’s ARKK ETF also added 165,024 shares of CRISPR Therapeutics AG (NASDAQ:CRSP) to its portfolio, valued at $9,706,711. The ...
Ibotta(NYSE:IBTA) reported second quarter 2025 earnings on August 13, 2025, with revenue of $86 million, a 2% year-over-year decline, and adjusted EBITDA of $17.9 million. Management cited a 48% ...
Ibotta shares plunged 34% after Q2 earnings missed forecasts, prompting multiple analyst downgrades and price target cuts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results